EUVIMEDEUVIMED entdecken
Crossref

Decision to operate on hepatocellular cancer patients is not driven by comorbidities in Louisiana

Annie Talbot, Denise Danos, Yong Yi, Lauren Maniscalco, Xiao-Cheng Wu, Omeed Moaven, Mary Maluccio, John Lyons

HPB · 2025

DOI: 10.1016/j.hpb.2025.01.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HPB, 2025. Verfasst von Annie Talbot und 7 weiteren Autor:innen. Beteiligte Einrichtung: LSU Department of Surgery School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The mortality rate of Hepatocellular cancer (HCC) in Louisiana is second worst in the United States. This has been linked to underutilization of curative treatment (CT). This study aimed to identify risk factors associated with underutilization of CT in Louisiana. METHODS: Patients with AJCC T1 HCC diagnosed from 2011 to 2020 were identified from the Louisiana Tumor Registry (LTR) using site and histology codes. Patients who underwent CT (ablation, resection, and transplantation) were compared to those who did not undergo CT. Logistic regression was performed and results reported as adjusted odds ratios. RESULTS: CT was utilized in 462 (37 %) of 1247 patients with T1 HCC. There were no significant differences observed in age, race, BMI, poverty, or rurality between CT and non-CT patients. The percentage of cirrhosis was similar in both groups (35.3 % vs. 37.7 %, NS). On multivariant analysis, lack of CT was independently associated with low socioeconomic status (SES; p = 0.040), treatment outside a COC center (p < 0.001), and lack commercial/private insurance (p < 0.001). CONCLUSION: Utilization of CT is driven not by comorbidities, but by insurance type, low SES, and treatment facility indicating the profound effect that care disparities have on HCC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatectomyHumansMaleFemaleLouisianaMiddle AgedComorbidityAgedRisk FactorsRegistriesHealthcare DisparitiesClinical Decision-Making

Autor:innen und Institutionen

  • LSU Department of Surgery School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA.
  • School of Public Health, LSU Health Sciences Center, New Orleans, LA, USA.
  • Louisiana Tumor Registry, LSU Health Sciences Center, New Orleans, LA, USA.
  • School of Public Health, LSU Health Sciences Center, New Orleans, LA, USA; Louisiana Tumor Registry, LSU Health Sciences Center, New Orleans, LA, USA.
  • LSU Department of Surgery School of Medicine, LSU Health Sciences Center, New Orleans, LA, USA; Department of Surgery, Our Lady of the Lake Regional Medical Center, Baton Rouge, LA, USA. Electronic address: john.lyons@f…

Zitieren

APA

Talbot, A., Danos, D., Yi, Y., Maniscalco, L., Wu, X. C., Moaven, O., Maluccio, M., & Lyons, J. (2025). Decision to operate on hepatocellular cancer patients is not driven by comorbidities in Louisiana. HPB. https://doi.org/10.1016/j.hpb.2025.01.013

Vancouver

Talbot A, Danos D, Yi Y, Maniscalco L, Wu XC, Moaven O, et al. Decision to operate on hepatocellular cancer patients is not driven by comorbidities in Louisiana. HPB. 2025. doi:10.1016/j.hpb.2025.01.013

BibTeX
@article{Talbot2025,
  author = {Talbot, Annie and Danos, Denise and Yi, Yong and Maniscalco, Lauren and Wu, Xiao-Cheng and Moaven, Omeed and Maluccio, Mary and Lyons, John},
  title = {Decision to operate on hepatocellular cancer patients is not driven by comorbidities in Louisiana},
  journal = {HPB},
  year = {2025},
  doi = {10.1016/j.hpb.2025.01.013}
}
Kostenlos starten →